Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04424446 · ClinicalTrials.gov registry record

Saliva as Source of Detection for SARS-CoV-2

A clinical trial of COVID-19, sponsored by National Institutes of Health Clinical Center (CC).

Completed
Registry status
456
Enrollment target
2
Study locations

NCT04424446: Completed study of COVID-19, sponsored by National Institutes of Health Clinical Center (CC).

NCT04424446 is a study of COVID-19 that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 456 participants, below the 38,463-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04424446, a study of COVID-19, has completed, sponsored by National Institutes of Health Clinical Center (CC).

COMPLETED
Registry status
456 participants
Enrollment target
2
Study locations

Study Summary

Background: Nasopharyngeal (NP) swabbing is being used to test for SARS-CoV-2 infection. For this, a swab is inserted deep into the back of the nose to collect a sample. It can cause discomfort for most people. Researchers want to find an easier way to collect samples. Objective: To learn if testing for SARSCoV-2 with a saliva sample only, a nasal swab from just the front part of the nostril only, or a saliva sample plus a nasal swab gives results that are as accurate as the NP swab. Eligibility: NIH staff members age 18 and older who are taking part in NIH CC SARS-CoV-2 surveillance. Design: The Occupational Medical Service (OMS) collects NP swabs as part of standard NIH staff screening. Participants will give 1 or 2 saliva samples and 1 or 2 nasal swabs when their NP swab is collected by OMS. If their NP swab was already collected, their OMS record will be reviewed for the result. If the NP swab result is positive, the participant will have another NP swab. At that time, they will also give 1 or 2 saliva samples and 1 or 2 nasal swabs. If the NP swab result is negative, they will give 1 or 2 saliva samples and 1 or 2 nasal swabs the next time they have an NP swab. For the saliva sample, participants will spit into a tube. For the nasal swab, the inside of the front part of the nostril will be swabbed. Participation ends after the study samples are collected. Participants can choose to keep giving saliva and nasal swab samples each time they have an NP swab.

Primary Outcome

Validate saliva or nasal swab as a source of detection for SARS-CoV-2.

Conditions Studied

Study Locations (2)

District of Columbia

  • Washington Hospital Center - Washington D.C.

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 456 participants
Start Date 2020-07-13
Est. Completion 2020-09-04

What the finished NCT04424446 record still lists

NCT04424446 is an observational study that tracks outcomes without assigning an intervention. The registered 456 participants enrollment target is mid-sized for trials with a published cap, below the 38,463-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).

The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 0 interventions.

NCT04424446 reports a single indexed study location in District of Columbia, Maryland.

Frequently Asked Questions

What is clinical trial NCT04424446 about?

NCT04424446 is a clinical study titled "Saliva as Source of Detection for SARS-CoV-2". Background: Nasopharyngeal (NP) swabbing is being used to test for SARS-CoV-2 infection. For this, a swab is inserted deep into the back of the nose to collect a sample. It can cause discomfort for most people. Researchers want to find an easier way to collect samples. Objective: To learn if test...

What is the current status of trial NCT04424446?

This trial is currently completed. The enrollment target is 456 participants. The study started on 2020-07-13. Estimated completion is 2020-09-04.

What conditions does trial NCT04424446 study?

This clinical trial studies the following conditions: COVID-19.

Who is sponsoring clinical trial NCT04424446?

This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04424446 being conducted?

This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04424446's enrollment target sits among peer trials

456 117th of 298 higher than 182 of 298 other COVID-19 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04462302 · 456 participants · NA

    An Internet-based Program to Help Cancer Survivors Manage Pain

  • NCT05820919 · 456 participants · NA

    Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase

  • NCT06254612 · 456 participants · Phase 2

    A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

  • NCT06457841 · 456 participants · NA

    Stress and Resilience

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04424446, the US trial registry maintained by the National Library of Medicine. NCT04424446 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.